Physician profile
Luis C Omphroy
NPI 1528121423
$24,520.30
in general payments reported to CMS, 2019-2025
41 companies · $5,093 in 2025
The $5,093 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,914 · 2020: $1,149 · 2021: $2,049 · 2022: $3,018 · 2023: $3,376 · 2024: $4,922 · 2025: $5,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,552.08 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,268.51 | 2021-2025 | Unity, Clareon, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $3,010.15 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Amgen INC. | $2,615.05 | 2019-2025 | Tepezza, Otezla, Repatha |
| Lilly USA, LLC | $1,999.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,595.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,315.62 | 2019-2025 | Jardiance, Synjardy |
| Bausch & Lomb Americas INC. | $1,186.85 | 2022-2025 | Envista Mx60 Iol, Stellaris, Envista Envy Iol |
| Glaukos Corporation | $956.24 | 2019-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $923.22 | 2019-2021 | |
| Abbvie INC. | $716.59 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $698.07 | 2020-2025 | Farxiga, Airsupra |
| Tarsus Pharmaceuticals, INC. | $606.95 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $602.30 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $492.30 | 2019-2021 | |
| Horizon Therapeutics Plc | $451.43 | 2023 | Tepezza, Krystexxa |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $409.88 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $398.67 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $397.26 | 2019-2024 | Cequa |
| Bayer Healthcare Pharmaceuticals INC. | $219.60 | 2023-2025 | |
| Radius Health, INC. | $194.29 | 2020-2023 | Tymlos |
| Abbott Laboratories | $182.25 | 2022-2023 | Freestyle Libre 3 |
| Dompe US, INC. | $154.45 | 2022-2024 | Oxervate |
| Biohaven Pharmaceutical Holding Company LTD. | $139.46 | 2022 | |
| Glaxosmithkline, LLC. | $130.68 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Kedrion Biopharma, INC. | $124.96 | 2025 | Coagadex |
| Exact Sciences Corporation | $106.13 | 2025 | |
| Arbor Pharmaceuticals, INC. | $89.30 | 2019-2020 | |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Rxsight INC | $72.49 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Esperion Therapeutics, INC. | $69.83 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $57.36 | 2020-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Novartis Pharmaceuticals Corporation | $43.76 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $35.72 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.17 | 2021 | |
| Eisai INC. | $24.17 | 2021 | |
| Insulet Corporation | $22.10 | 2023 | Omnipod |
| Kala Pharmaceuticals, INC. | $21.50 | 2021 | |
| Shire North American Group INC | $20.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.20 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.56 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $18.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Omphroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.